3Q18 Earnings Conference Call November 1, 2018 ITGR: 3Q18 Earnings - - PowerPoint PPT Presentation

3q18 earnings conference call
SMART_READER_LITE
LIVE PREVIEW

3Q18 Earnings Conference Call November 1, 2018 ITGR: 3Q18 Earnings - - PowerPoint PPT Presentation

3Q18 Earnings Conference Call November 1, 2018 ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 1 Presentation of Financial Information & Forward-Looking Statements Historical financial and operating data in this presentation


slide-1
SLIDE 1

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 1

3Q18 Earnings Conference Call

November 1, 2018

slide-2
SLIDE 2

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 2

Presentation of Financial Information & Forward-Looking Statements

Historical financial and operating data in this presentation reflect the consolidated results of Integer for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include Adjusted Net Income, Adjusted Diluted EPS, Earnings Before Interest Taxes Depreciation and Amortization (EBITDA), Adjusted EBITDA, and organic growth rates should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of these non-GAAP financial measures to the most comparable GAAP measures, please refer to the appendix to this presentation and the earnings release associated with this quarterly period which can be found in the investor relations section of our corporate website (investor.integer.net). Statements made in this presentation whether written or oral may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are based on the company’s current expectations and speak only as of November 1, 2018. The Company’s actual results could differ materially from those stated or implied by such forward-looking statements. The Company assumes no obligation to update forward-looking information, including information in this presentation, to reflect changed assumptions, the

  • ccurrence of unanticipated events or changes in future operating results, financial conditions or prospects.
slide-3
SLIDE 3

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 3

Agenda

  • Opening Comments
  • Financial Results
  • Product Line Review
  • 2018 Outlook
  • Question & Answer Period
slide-4
SLIDE 4

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 4

Opening Comments

slide-5
SLIDE 5

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 5

Strong Financial Results…Executing Strategy…Building Team

Integer delivered another strong quarter

  • f sales and profit

growth Launched Operational Strategic Imperatives Continued Building Leadership Team

Financial Results

  • 3Q results support improved guidance
  • Revenue guidance increased to 6% - 7% growth
  • EPS guidance increased primarily due to lower taxes and interest expense
  • Continued Deleveraging
  • Paid down $595 million of debt in 3Q
  • Leverage ratio at 3.7 times adjusted EBITDA versus 5.6 at the beginning of 2018

Strategy

  • Launched execution of multi-year Operational Strategic Imperatives in

September with Top 100 Senior Leaders

  • Transitioning to a new sales organization structure in 4Q to drive customer

focused growth strategies and increase accountability for sales growth

Leadership

  • Jason Garland joined as EVP/CFO to bring strong operational finance

leadership to execution of Operational Strategic Imperatives

  • As previously announced, Jeremy Friedman, former COO/Interim CFO,

retiring at end of 2018. Customer Operational Strategic Imperatives transitioned to Payman Khales (Pres. C&V) and Tony Gonzalez (Pres. CRMN)

slide-6
SLIDE 6

Financial Results

slide-7
SLIDE 7

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 7

$29 $35

3Q17 3Q18

$60 $67

3Q17 3Q18

$284 $305

3Q17 3Q18

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure (2) Organic growth for Sales excludes the impact of foreign currency exchange rates (3) Organic growth for Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS exclude the impact of foreign currency reported in other (income) loss, net

3Q18 Adjusted Financial Results(1)

($ in millions, except per share amounts)

Adjusted Sales Adjusted EBITDA Adjusted Net Income

$305

Reported

$68

FX adjusted

$36

FX adjusted

$63

FX Adjusted As reported GAAP and Non-GAAP numbers Foreign currency impact on reported GAAP and Non-GAAP numbers FX Adjusted Reported Reported Reported

$31

FX Adjusted Reported

$285

Reported

7%

  • rganic(2)

9%

  • rganic(3)

15%

  • rganic(3)

7% reported 10% reported 18% reported

% Growth

Reported

0.91 $ 1.06 $

FX Adjusted

0.98 $ 1.10 $ Adj. EPS

FX Adjusted FX Adjusted

slide-8
SLIDE 8

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 8

4% 6% 7% 8% 9%

3Q17 4Q17 1Q18 2Q18 3Q18

0% 20% 40% 0% 4% 8% 12%

Year-over-Year Sales Improvement Continues(1)

Trailing 4 Quarters

0%

Integer

(1) Excludes impact from changes in foreign currency exchange rates

Cardio & Vascular Advanced Surgical, Orthopedic & Portable Medical

(6)% (2)% 2% 6% 0% 5% 10% 15%

Non-Medical (Electrochem) Cardiac & Neuromodulation

slide-9
SLIDE 9

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 9

Adj. EPS $0.91 $0.25 $(0.12) $0.02 $0.03 $(0.04) $1.06

$60 $67 3Q17 3Q18

(1) Includes $0.02 unfavorable impact due to year-over-year share dilution Note: Amounts may not sum due to rounding

Adjusted EBITDA

Adjusted EBITDA & Adjusted Net Income

($ in millions except per share amounts)

Incentive Compensation FX

  • $10 from Operations
  • $1 FX
  • $(4) Incentive

Compensation

Operational Improvement Tax Rate (1)

$29 $9 $(4) $1 $1 $(1) $35

3Q17 Operational Improvement Incentive Compensation FX Interest Tax Rate 3Q18

Adjusted Net Income

(1)

slide-10
SLIDE 10

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 10

$38 $34 $46 $21 $54

3Q17 4Q17 1Q18 2Q18 3Q18

$27 $21 $36 $13 $40

3Q17 4Q17 1Q18 2Q18 3Q18 5.8x 5.6x 5.4x 5.1x 3.7x 3Q17 4Q17 1Q18 2Q18 3Q18 $5 $7 $7 $7 $7 $33 $15 $43 $18

$38 $22 $50 $25

3Q17 4Q17 1Q18 2Q18 3Q18

Continued Deleveraging

Debt Payments

($ in millions) (1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures, net (2) Leverage calculated as Total Debt less Cash and Cash Equivalents divided by trailing 4 quarter Adjusted EBITDA (3) 3Q18 Accelerated Repayments totaled $588M; $548 from divestiture proceeds plus $40M from operations

Cash Flow From Ops

($ in millions)

Free Cash Flow (1)

($ in millions) Accelerated Repayment from Divestiture Proceeds Accelerated Repayment Required Repayment

  • Reduced leverage ratio to

3.7 times adjusted EBITDA

  • $548M from divestiture

proceeds

  • $40M in additional

accelerated pay down

  • No significant maturities

until 2021; well within covenants

Leverage (2)

$595

$40 $548

(3)

slide-11
SLIDE 11

Product Line Review

slide-12
SLIDE 12

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 12

7% 11% 10% 13% 9% 3Q17 4Q17 1Q18 2Q18 3Q18 $516 $531 $544 $562 $575 3Q17 4Q17 1Q18 2Q18 3Q18

Offering a full-range of services for the design, development, and manufacturing of diagnostic and interventional cardiac and endovascular delivery and retrieval devices, along with comprehensive supply-chain solutions

Cardio & Vascular

Steerable Sheaths Catheters & Sheaths Guidewires, Stylets & Accessories Introducers 0%

% Change

Trailing 4-Quarter Sales

($ in millions)

9% 10% 10% 11% 11%

  • 3Q18 year-over-year growth driven by continued strong

demand in the electrophysiology market stemming from customer share gains & new product launch and timing from a customer inventory replenishment

  • Trailing 4-quarter sales growth of 11% driven by continued

strong demand and market penetration in the focus markets

  • f electrophysiology, structural heart and peripheral vascular
  • Expect growth trend to remain above market from increased

focus on high growth C&V market segments

Organic Quarterly Y-o-Y Growth

slide-13
SLIDE 13

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 13

$427 $428 $433 $443 $451 3Q17 4Q17 1Q18 2Q18 3Q18 (6)% 1% 5% 9% 8% 3Q17 4Q17 1Q18 2Q18 3Q18

Providing technology solutions for the active implantable medical device industry by partnering with customers to bring high-quality productsto established and emerging markets – from initial concept through high-volume manufacturing

Cardiac & Neuromodulation

0%

% Change

Trailing 4-Quarter Sales

($ in millions)

Pulse Generator Components & Assemblies Leads & Lead Components, Adaptors & Assemblies Pulse Generators & External Solutions (Programmers, Chargers, Patient Devices) (4)% (2)% (0)% 2% 6%

  • CRM growth driven by increased components market

penetration & lower 2017 comparables from customer inventory adjustments. Neuro growth driven by spinal cord stimulation market demand and increased components market penetration

  • Trailing 4-quarter CRM sales slightly ahead of market

growth and neuromodulation sales running significantly ahead of market due to accelerating demand in finished devices and leads

  • Expect sales to decrease in 4Q18 compared to extremely

strong 4Q17

Organic Quarterly Y-o-Y Growth

slide-14
SLIDE 14

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 14

$114 $115 $121 $127 $130 3Q17 4Q17 1Q18 2Q18 3Q18 7% 4% 25% 21% 9% 3Q17 4Q17 1Q18 2Q18 3Q18

Advanced Surgical, Orthopedics & Portable Medical

Supporting our divested AS&O business and providing technologies and solutions to Portable Medical markets

Orthopedic Implants & Instruments Core Battery Pack Assemblies Li-Ion Battery Packs Electrosurgical Accessories 0%

% Change

Trailing 4-Quarter Sales

($ in millions)

Organic Quarterly Y-o-Y Growth

6% 8% 10% 13% 13%

  • 3Q18 sales increase driven by above market growth in

advanced surgical and orthopedic products

  • Trailing 4-quarter sales growth strong due to robust 1st

half 2018 market demand primarily in Portable Medical

  • Sales expected to level off from strong first half to be

more in line with overall market growth

slide-15
SLIDE 15

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 15

$54 $57 $58 $58 $55 3Q17 4Q17 1Q18 2Q18 3Q18 71% 30% 12% (5)% (18)% 3Q17 4Q17 1Q18 2Q18 3Q18

Electrochem

Enhancing lives worldwide by providing superior power solutions that enable the success and advancement of our customers’ critical applications

Battery Packs Battery Chargers Battery Cells 0%

% Change

Trailing 4-Quarter Sales

($ in millions)

23% 37% 41% 22% 3%

  • 3Q18 sales decline due to timing of energy customer

inventory adjustments and planned phase out of certain rechargeable battery pack products

  • Trailing 4-quarter trend reflects flattening of North American

drilling activity.

  • Expect growth in 2019 from new customers and products

and renewed military market government funding

Organic Quarterly Y-o-Y Growth

slide-16
SLIDE 16

2018 Revised Outlook

slide-17
SLIDE 17

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 17

2017 2018 Outlook 2017 2018 Outlook 2017 2018 Outlook

2018 Outlook

Adjusted EPS

$1,131 $3.09 $1,195 - $1,210 $3.55 - $3.70

($ in millions except per share amounts)

Growth % 6% - 7% 15% - 20%

Adjusted Sales

$234 $255 - $265

9% - 13%

Adjusted EBITDA

$1,175 - $1,200 $255 - $265 $3.35 - $3.65 Prior Outlook

slide-18
SLIDE 18

$47 $103 $120

FY16 FY17 FY18

$106 $149

FY16 FY17 FY18

$29 $31 $30 $15 $98

$44 $129 $145

2016 2017 2018

Debt Payments

($ in millions) (1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures, net (2) Leverage calculated as Total Debt less Cash and Cash Equivalents divided by Trailing 4 Quarter Adjusted EBITDA (3) Reflects debt payments excluding $55M of borrowings used to fund $76M of cash provided to Nuvectra as part of the spin-off on March 14, 2016.

Cash Flow From Ops

($ in millions)

Free Cash Flow(1)

($ in millions)

Leverage(2)

$160+ $110+ $665+ Prior Outlook ~$695

Outlook

Accelerated Repayment Required Repayment

6.1x 5.6x 3.6x

YE16 YE17 YE18

Outlook Outlook Outlook

(3)

~ $145+

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 18

~$120 ~$165

Increased Cash Flow Outlook

slide-19
SLIDE 19

Cardio & Vascular Neuromodulation Electrochem

Focused Strategy to Drive Long-term Growth

Invest to Grow Protect & Preserve Improve Profitability

Portable Medical

Portfolio Strategy Operational Strategy: Strategic Imperatives

Cardiac Rhythm Management How we win in the markets we serve How we achieve excellence in everything we do

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 19

slide-20
SLIDE 20

Summary

Vision

Enhance patient’s lives by being our customers partner of choice

Strategic Imperatives

  • Sales Force Excellence
  • Market Focused Innovation
  • Manufacturing Excellence
  • Business Process Excellence
  • Performance Excellence
  • Leadership Capability

Clear Goals

  • Sales Growth Above Market
  • Profit Growth 2x Sales Growth
  • Earn a Valuation Premium

Financial Results

  • 3Q results support slightly improved guidance
  • Continued Deleveraging

Strategy

  • Launched execution of multi-year Operational Strategic Imperatives
  • Transitioning to a new sales organization structure in 4Q

Leadership

  • Jason Garland joined as EVP/CFO
  • Jeremy Friedman, former COO/Interim CFO, retiring at YE18

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 20

slide-21
SLIDE 21

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 21

APPENDIX

slide-22
SLIDE 22

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 22

Historical Financial Results

($ in millions except per share amounts)

Adjusted Sales Adjusted EPS

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EPS to the most directly comparable GAAP measure (2) The quarterly and annual EPS numbers are calculated independently and may not sum to the total (3) Excludes impact of foreign currency reported in other gain or loss, net Impact of foreign currency reported in other gain or loss, net Adjusted EPS, as reported

Organic Adjusted EPS(3)

$0.58 $0.91 $0.98 $0.89 $0.66 $1.01 $1.10

(1) (2)

$265 $280 $285 $301 $292 $313 $305

slide-23
SLIDE 23

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 23

2018 Full-Year Outlook

($ in millions except per share amounts)

2018 Outlook Prior Guidance

(Non-GAAP)

Growth Updated Guidance

(Non-GAAP)

Growth Adjusted Revenue $1,175 - $1,200 4% to 6% $1,195 - $1,210 6% to 7% Adjusted Net Income $110 - $120 11% to 21% $117 - $122 18% to 23% Adjusted EBITDA $255 - $265 9% to 13% $255 - $265 9% to 13% Adjusted Earnings per Diluted Share $3.35 - $3.65 8% to 18% $3.55 - $3.70 15% to 20%

slide-24
SLIDE 24

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 24

2018 Full-Year Outlook – Supplemental Items Affecting Cash Flow

($ in millions, except per share amounts)

slide-25
SLIDE 25

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 25

Non-GAAP Reconciliation

Net Income and Diluted EPS Reconciliation – QTD

See the Footnotes to this table on Slide 26 of this presentation ($ in thousands, except per share amounts)

slide-26
SLIDE 26

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 26

Footnotes to Non-GAAP Reconciliation

slide-27
SLIDE 27

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 27

Non-GAAP Reconciliation

3Q18 Net Income and Diluted EPS Reconciliation – Detailed View

($ in thousands, except per share amounts)

slide-28
SLIDE 28

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 28

Non-GAAP Reconciliation

EBITDA and Adjusted EBITDA Reconciliation

($ in thousands)

slide-29
SLIDE 29

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 29

Non-GAAP Reconciliation

Organic Sales Growth Rate Reconciliation (% Change)

a) Represents adjustment to third quarter and year-to-date 2017 sales to exclude the net impact of the LSA. b) Third quarter and year-to-date 2018 sales were positively impacted by $0.1 million (negative impact) and $2.3 million (positive impact), respectively, due to foreign currency exchange rate fluctuations, primarily in our Cardio & Vascular product line.

slide-30
SLIDE 30

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 30

Non-GAAP Reconciliation

Non-GAAP Organic Growth Rate Reconciliation (% Change)

NM calculated change not meaningful

(a) Represents the impact to our growth rate from our Non-GAAP adjustments. (b) Represents the impact to our growth rate due to changes in foreign currency exchange rates

slide-31
SLIDE 31

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 31

Non-GAAP Reconciliation

2018 Full-Year Outlook(a)

($ in millions, except per share amounts)

slide-32
SLIDE 32

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 32

Capitalization

($ in millions) As Reported Original 6/30/18 9/28/18 9/28/18 Rate Rate Rate

Cash and Cash Equivalents $23 $200m Revolver due 2020

  • L + 325

L + 325 L + 250 Term Loan A due 2021 314 L + 325 L + 325 L + 250 Term Loan B due 2022 658 L + 425 L + 325 L + 300 Total Secured Debt $972 Senior Unsecured Notes due 2023

  • 9.125%

9.125%

  • Total Debt

$972 Net Debt $949 Continuing Operations statistics LTM Adjusted EBITDA $256 LTM Cash Interest Expense 52 LTM Capital Expenditures 36 Credit statistics Net Total Debt / LTM Adjusted EBITDA 3.7x LTM Adjusted EBITDA / Cash Interest Expense 4.9x

(1) (1) Gross debt outstanding, not reduced for unamortized discount and debt issuance costs

slide-33
SLIDE 33

ITGR: 3Q18 Earnings Conference Call / November 1, 2018 / Page 33

Contact Information

Tony Borowicz

SVP, Strategy, Corporate Development & Investor Relations

Integer

Tony.Borowicz@Integer.net www.integer.net

(O) 716.759.5809